ARTICLE | Clinical News
XP23829: Development discontinued
October 12, 2015 7:00 AM UTC
XenoPort discontinued development of XP23829 and plans to partner the compound and other pipeline candidates to focus on commercializing Horizant gabapentin enacarbil. In September, XenoPort reported...